DURECT (NASDAQ:DRRX) is down 13% premarket on light volume following yesterday’s 6-6 vote from an FDA advisory committee on bupivacaine extended-release solution for the treatment of post-surgical pain.
The company’s application is a resubmission. It received a CRL in February 2014 in response to its first filing citing the need for more safety data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.